Pharmaceutical - Asia-Pacific, Merck & Co

Filter

Current filters:

Asia-PacificMerck & Co

Popular Filters

Merck & Co partners with Cipla for Indian marketing of raltegravir

Merck & Co partners with Cipla for Indian marketing of raltegravir

21-02-2014

US pharma giant Merck & Co, known as MSD outside North America, has announced the formation of an India-specific…

Anti-viralsAsia-PacificCiplaIndiaIsentressMarkets & MarketingMerck & CoPharmaceuticalRaltegravir Tablets

India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector

17-02-2014

The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

Astellas gains Japanese clearance for diabetes drug Suglat

Astellas gains Japanese clearance for diabetes drug Suglat

20-01-2014

Japanese drug major Astellas Pharma has obtained the marketing approval of selective SGLT2 inhibitor…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalMerck & CoPharmaceuticalRegulationSuglat

Tivicay set to become leading HIV treatment by 2016

Tivicay set to become leading HIV treatment by 2016

15-01-2014

Antiretroviral drug Tivicay (dolutegravir) is set to become the leading integrase inhibitor for the treatment…

Anti-viralsAsia-PacificEuropeIsentressJanssenMarkets & MarketingMerck & CoPharmaceuticalPrezistaTivicayUSAViiV Healthcare

New Zealand views access to sugammadex and atomoxetine and baclofen injection funding

02-12-2013

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on the following proposals…

Asia-PacificBridionEli LillyLioresal IntrathecalMerck & CoNeurologicalNew ZealandPharmaceuticalRegulationStrattera

Merck & Co to co-promote diabetes agent ipragliflozin in Japan

02-09-2013

Japanese drug major Astellas Pharma (TYO: 4503) has entered into a co-promotion agreement in Japan with…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalLicensingMarkets & MarketingMerck & CoPharmaceutical

Growth drivers for China's type 2 diabetes market

09-08-2013

The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

New Zealand consults on Victrelis listing and some Pegasys amendments

19-07-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list boceprevir…

Anti-viralsAsia-PacificBiotechnologyMerck & CoPegasysPharmaceuticalRegulationRocheVictrelis

Japan vaccines briefs: Gardasil and Cervarix; Daiichi Sankyo files NDA

21-06-2013

The Japanese Ministry of Health, Labor and Welfare has decided to withdraw its recommendation for a vaccination…

Asia-PacificCervarixDaiichi SankyoGardasilGlaxoSmithKlineMerck & CoPharmaceuticalRegulationVaccinesWomen's Health

Merck & Co opens new $120 million manufacturing plant in China

19-04-2013

US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Australia to subsidize groundbreaking hepatitis C drugs under PBS

19-02-2013

The Australian government said on February 19 that it is extended subsidies of important medicines each…

Anti-viralsAsia-PacificFinancialHealthcareIncivoJohnson & JohnsonMerck & CoPharmaceuticalPricingVictrelis

New Zealand considers listing Merck & Co's Bridion

30-01-2013

New Zealand's Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to list the…

Asia-PacificBridionFinancialMerck & CoNeurologicalPharmaceuticalRegulation

South Korea's type 2 diabetes drug market to grow to over $550 million in 2016

23-10-2012

The type 2 diabetes therapeutic market in South Korea will grow 11% annually from $330 million in 2011…

AmylinAsia-PacificBydureonDiabetesJanumetJanuviaMarkets & MarketingMerck & CoNovo NordiskPharmaceuticalVictoza

New Zealand's PHARMAC to fund alternative treatments for asthma, scabies from Merck

31-07-2012

New Zealand's Pharmaceutical Management Agency PHARMAC is to fund a treatment for pre-schoolers with…

Asia-PacificDermatologicalsHealthcareMerck & CoPharmaceuticalPricingRespiratory and PulmonarySingulairStromectil

Australia extends HPV vaccine to schoolboys

12-07-2012

In what is claimed "a world first" by the Department of Health and Ageing, Australian schoolboys will…

Asia-PacificGardasilHealthcareMerck & CoOncologyPharmaceuticalVaccines

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

04-05-2012

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

Back to top